A Phase 4 interventional study of ceftizoxime in Caesarean, sponsored by University of Khartoum. Completed at 1 site in Sudan. Open to female participants aged 14 Years to 45 Years. Per ClinicalTrials.gov, last updated 2013-01-17.
Sponsored by University of Khartoum · Phase 4, Interventional, and Prevention
Ceftizoxime (Cefizox) will reduce post Cesarean delivery febrile morbidity.
University of Khartoum is the lead sponsor of 14 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
ceftizoxime (cefizox) as single dose of 1 g at the interval of 30-60 minutes before the incision
Drug: ceftizoxime
ceftizoxime (cefizox) injection either after clamping the cord
Also known as: cefizox
reducing post Cesarean section febrile morbidity
reducing infection rate
Time frame: 4 days
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Khartoum